At‑home brain stimulation cleared

Brain stimulation for depression used to mean going to a clinic, sitting in a chair, and letting a machine do the work under staff supervision. The new twist is that the United States Food and Drug Administration has now approved devices that can be prescribed for use at home, with a doctor still directing care from a distance. (fda.gov) (patientcareonline.com) This kind of treatment is called neuromodulation, which means trying to change how brain circuits fire without surgery. Think of it less like adding a new chemical and more like nudging a dimmer switch that controls activity in a mood-related network. (health.harvard.edu) (brainfacts.org) One home device uses transcranial direct current stimulation, which sends a very weak direct current through electrodes on the scalp. In the Food and Drug Administration’s approval summary for Flow FL-100, the headset delivers 2.0 milliamps through saline-soaked pads placed on the head. (fda.gov) The idea behind that current is simple: brain cells are electrical, and a small outside current can make a target area a little easier or harder to activate. For depression, companies have focused on the prefrontal cortex, a region tied to mood regulation and stress response. (fda.gov) (patientcareonline.com) The first big at-home approval came on December 8, 2025, when the Food and Drug Administration approved Flow FL-100 for adults 18 and older with moderate to severe major depressive disorder in a current episode. That approval allows use either by itself or alongside medication in patients who are not considered treatment-refractory to medication. (fda.gov) The evidence for that headset came from a 10-week randomized trial in 174 adults in the United States and the United Kingdom. People using active stimulation improved by 9.41 points on the 17-item Hamilton Depression Rating Scale, compared with 7.14 points for the sham group. (nature.com) (patientcareonline.com) But the Food and Drug Administration did not describe that benefit as clean and settled. In its own review, the agency said there was “moderate level of uncertainty of benefit” because of unblinding concerns, no prespecified clinically meaningful threshold on the depression scale, and conflicting results in the broader literature. (fda.gov) A second home approval followed on December 31, 2025, for ProlivRx from Neurolief. That system is prescription-only, approved for use at home or in clinic, and intended only as an add-on treatment for adults with major depressive disorder who did not get satisfactory improvement from at least one antidepressant. (fda.gov) (psychiatrictimes.com) ProlivRx does not use the same approach as the Flow headset. The Food and Drug Administration says it provides focal external combined occipital and trigeminal afferent stimulation, which means it targets nerve pathways linked to the back of the head and the face rather than sending the standard direct current pattern used by transcranial direct current stimulation. (fda.gov) (psychiatrictimes.com) What changed over the last year is not that brain stimulation suddenly became new. What changed is that the Food and Drug Administration has now signed off on depression devices designed to leave the clinic, which turns questions about electrode placement, adherence, remote supervision, and insurance coverage into practical problems for ordinary households instead of specialty centers. (fda.gov 1) (fda.gov 2) That shift could widen access for patients who cannot manage daily clinic visits, but it also means real-world results will depend on whether people actually complete sessions at home the way trial participants did under structured monitoring. The approvals are real, the physician oversight is still built in, and the next test is what happens when depression treatment moves from a supervised room into a living room. (nature.com) (fda.gov)